Mangoceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
Mangoceuticals, Inc. filed a Current Report on Form 8-K dated May 1, 2023, with the filing signed May 4, 2023. The filing reports executive appointments, compensation arrangements, and related disclosures. It does not present financial statements or results for a reporting period.
Key Financial and Operating Metrics
- The filing text does not provide revenue, net income, cash flow, margins, debt, liquidity, or other operating metrics.
- Annual salary for newly appointed Chief Operating Officer Amanda Hammer: $150,000.
- Annual salary for Chief Executive Officer and Chairman Jacob Cohen increased from $180,000 to $300,000, effective May 1, 2023.
- Hammer received a sign-on grant of 75,000 fully vested common shares.
- Hammer received options to purchase 150,000 common shares at an exercise price of $1.10 per share. The options vest in 50,000-share increments annually while the employment agreement remains in effect and are exercisable for ten years.
Material Changes Versus the Prior Comparable Period
- Effective May 1, 2023, Amanda Hammer was appointed Chief Operating Officer.
- Jonathan Arango ceased serving as COO but remained President, Secretary, and a director.
- The company entered into a three-year employment agreement with Hammer, expiring May 1, 2026, with automatic one-year renewals unless either party provides at least 60 days’ notice.
- CEO Jacob Cohen’s annual salary was increased by $120,000, or approximately 66.7%.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- The filing provides no revenue or earnings guidance.
- Hammer is eligible for a discretionary cash bonus targeted at 100% of base salary, as well as potential additional discretionary equity or cash awards.
- Termination provisions may require salary, bonus, severance, health-insurance payments, and accelerated vesting of equity awards in specified circumstances, including termination by the company without cause or by Hammer for good reason.
- Severance eligibility is generally conditioned on execution of a release and compliance with confidentiality, invention-assignment, non-solicitation, and non-compete obligations.
- Hammer is subject to non-compete and non-solicitation restrictions during employment and for twelve months afterward. The filing notes that she could nevertheless use industry experience gained at the company to compete after employment ends.
- The agreement includes a targeted bonus and equity compensation that could increase future compensation expense and potential share dilution.
Important Facts for Investors to Verify
- Review the full employment agreement and stock option agreement filed as Exhibits 10.1 and 10.2.
- Verify the issuance of 75,000 common shares and the terms, vesting, and dilution impact of the 150,000 options.
- Assess the financial impact of the CEO salary increase and the COO’s base salary, targeted bonus, severance rights, and other benefits.
- Confirm whether subsequent filings disclose additional executive compensation, equity issuances, or changes to the employment arrangements.
- Use the company’s periodic reports to verify revenue, profitability, cash balances, liquidity, debt, and operating outlook, none of which are provided in this Form 8-K.